Skip to main content

Table 4 Antimicrobial susceptibility of major Gram-negative bacteria

From: Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis

Antibacterial Major Gram-negative bacteria, N (%) of resistant strains
A. baumannii (n = 57) K. Pneumoniae (n = 49) S. Maltophilia (n = 10) P.aeruginosa (n = 7) E. coli (n = 8)
Ampicillin 49 (100) 7 (87.5)
Ampicillin sulbactam 53 (93.0) 44 (89.8) 2 (25.0)
Piperacillin 53 (93.0) 43 (87.8) 1 (14.3) 7 (87.5)
Piperacillin tazobactam 52 (91.2) 38 (77.6) 1 (14.3) 1 (12.5)
Amoxicillin clavulanate 57 (100) 42 (85.7) 1 (12.5)
Cefazolin 48 (98.0) 7 (87.5)
Cefuroxime 43 (87.8) 6 (75.0)
Ceftriaxone 52 (91.2) 41 (83.7) 6 (75.0)
Ceftazidime 52 (91.2) 41 (83.7) 9 (90.0) 1 (14.3) 3 (37.5)
Cefoperazone sulbactam 45 (78.9) 39 (79.6)
Cefepime 53 (93.0) 41 (83.7) 1 (14.3) 5 (62.5)
Aztreonam 57 (100) 41 (83.7) 2 (28.6) 2 (25.0)
Cefoxitin 41 (83.7) 0 (0)
Meropenem 52 (91.2) 37 (75.5) 3 (42.9) 0 (0)
Imipenem 52 (91.2) 37 (75.5) 3 (42.9) 0 (0)
Amikacin 48 (84.2) 36 (73.5) 0(0) 0 (0)
Gentamicin 52 (91.2) 39 (79.6) 0(0) 2 (25.0)
Tobramycin 50 (87.7) 32 (65.3) 2 (25.0)
Levofloxacin 52 (91.2) 39 (79.6) 3 (30.0) 2 (28.6) 6 (75.0)
Ciprofloxacin 52 (91.2) 43 (87.8) 2 (28.6) 6 (75.0)
Sulfamethoxazole trimethoprim 48 (84.2) 36 (73.5) 0 (0) 4 (50.0)
Minocycline 16 (28.1) 23 (46.9) 0 (0) 2 (25.0)
Tigecycline 0 (0) 1 (1.7) 0 (0)
ESBL 43 (87.8) 6 (75.0)
  1. Note:- Not detected